This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB CI
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment DJ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden MT
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024 CI
Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024. CI
Sobi to Expand in South Korea via Rare Disease JV with Handok MT
US Futures, European Stocks Mixed DJ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says MT
Transcript : Swedish Orphan Biovitrum AB, Q4 2023 Earnings Call, Feb 08, 2024
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024 CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says MT
Ericsson: new CFO in early April CF
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health... Our Logo
Swedish Orphan Chairman Steps Down, Successor Named MT
Chart Swedish Orphan Biovitrum AB
More charts
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
270 SEK
Average target price
329.6 SEK
Spread / Average Target
+22.07%
Consensus
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. News Swedish Orphan Biovitrum AB
  5. Sobi Finalizes Inaugural SEK3 Billion Bond Issue